原發性免疫缺陷症市場 (各疾病:抗體不全，細胞免疫力缺乏、先天性免疫疾病、各檢查、各治療、各地區) -全球產業分析、規模、佔有率、成長、趨勢，及2015∼2023年的預測
Primary Immunodeficiency Diseases Market (By Disease: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder; By Test; By Treatment; By Geography) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
|出版商||Transparency Market Research||商品編碼||347757|
|出版日期||內容資訊||英文 117 Pages
|原發性免疫缺陷症市場 (各疾病:抗體不全，細胞免疫力缺乏、先天性免疫疾病、各檢查、各治療、各地區) -全球產業分析、規模、佔有率、成長、趨勢，及2015∼2023年的預測 Primary Immunodeficiency Diseases Market (By Disease: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder; By Test; By Treatment; By Geography) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023|
|出版日期: 2015年11月24日||內容資訊: 英文 117 Pages||
This report on the primary immunodeficiency diseases (PIDD) market studies the current as well as future prospects of the market. The stakeholders of this report include pharmaceuticals companies, diagnostic kits providers, distributors, care providers and insurance companies (payers) and other intermediaries engaged in PIDD as well as new entrants that are planning to enter in this segment. This report comprises an elaborate executive summary with a market snapshot providing overall information of various segments and sub-segments considered in the study scope. The executive summary also provides overall information and data analysis of the PIDD market with respect to the leading market segments based on Disease, Test, Treatment and Geography. The market revenue in terms of USD million for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all segments and sub-segments considered under the scope of study, considering 2014 as the base year. Pipeline analysis (qualitative) for Phase I, II candidates whereas a detailed quantitative aspect (US$ Mn) for III drugs are illustrated in the market overview chapter.
The report analyzed the PIDD market from four prominent segments: by Disease, by Test, by Treatment and by Geography. In terms of market by disease the overall market is segmented into three broad categories: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder. The antibody deficiency market is further analyzed and estimated for Agammaglobulinaemia, Common Variable Immune Deficiency, Selective IgA Deficiency, IgG Subclass Deficiency and Others. Whereas, cellular immunodeficiency market is sub-segmented into Ataxia Telangiectasia, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome, DiGeorge Syndrome and Others. The innate immune disorder market include Complement Deficiencies, Hyper IgE Syndrome and Others. Moreover this report also studies the global market by test for diagnosis which encompasses blood test and prenatal testing. The global PIDD market by treatment include both qualitative and quantitative analysis for immunoglobulin replacement therapy, antibiotics therapy, stem cell and gene therapy and others.
Geographically the market is divided into four major regions: North America, Europe, Asia Pacific and Rest of the World. The North America market incorporates The United States and Canada. The Europe region is accessed for Germany, United Kingdom and Rest of Europe. The Asia Pacific (APAC) market is sub-segmented into India, China and Rest of APAC. Rest of the World (RoW) include Latin America, Middle East and North Africa and Rest of RoW
Each of the aforementioned segments has been analyzed in detail for market trends, recent developments, outlook, and opportunities. The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that currently have strong impact on the global PIDD market which could influence the market in the future as well. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition between leading market players in the U.S. market. Porter's five forces analysis is also explained in this section to understand the market in U.S. considering different parameters that have an impact on the sustainability of the companies operating in the market.
The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their respective market shares across the globe. The recommendations section included in the report would assist existing market players in targeting the end users and stakeholders of PIDD and also to those aiming to seek an entry. The report also profiles major players in the PIDD market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Some of the leading companies operating in primary immunodeficiency diseases market across the globe. These encompasses Baxter International, Inc., Biotest AG, CSL Behring LLC, Bio Products Laboratory Ltd., Kedrion S.p.A., LFB S.A., Octapharma AG and Grifols S.A.
The global primary immunodeficiency diseases market is segmented into the following categories: